Clarametyx Fortifies Leadership for Late-Stage Biofilm Therapy Push

COLUMBUS, OH – April 02, 2026 – By Jennifer Anderson

Clarametyx Biosciences, a clinical-stage biotechnology company developing therapies to combat biofilm-driven diseases, has announced a significant strengthening of its executive team. The promotions of Dr. Veronica Hall to Chief Development Officer and Head of R&D and Dr. Brendan Doran to Chief Operating Officer signal a strategic move to accelerate the company’s pipeline as it prepares for later-stage clinical trials.

The leadership appointments come as Clarametyx advances its lead candidate, CMTX-101, an innovative antibody therapy designed to disrupt the protective shields built by bacteria. This move underscores the company's confidence in its technology and its commitment to scaling operations for the critical phases ahead.

“As we rapidly move toward later stages of clinical development, these promotions sharpen our execution and strategic focus,” said David V. Richards, Chief Executive Officer. “Veronica will lead the strategic advancement of our development pipeline, bringing her deep scientific expertise and cross-functional leadership to drive our programs from research through clinical execution, while Brendan will leverage his operational expertise to scale our clinical infrastructure as we grow. Strengthening our C-suite with these promotions will accelerate our momentum to deliver this important therapeutic innovation to patients as quickly as possible.”

A Strategic Pivot for Clinical Acceleration

The executive reshuffle at Clarametyx is more than a routine update to the masthead; it represents a calculated pivot to fortify the company for its next chapter. With its lead program, CMTX-101, having successfully completed a Phase 1b/2a trial, the company is transitioning from early-stage research into the more complex and resource-intensive world of late-stage clinical development. This phase demands a dual focus on rigorous scientific advancement and robust operational execution, a balance the new leadership structure is designed to achieve.

Dr. Hall’s promotion places a founding scientific leader at the helm of R&D strategy, ensuring continuity and deep institutional knowledge guide the path forward. Her role will be crucial in designing subsequent trials and exploring new applications for the company’s platform. Simultaneously, Dr. Doran’s appointment as COO addresses the immense logistical challenges of scaling up clinical operations. His focus will be on building the infrastructure needed to run larger, multi-center trials efficiently, manage supply chains, and ensure regulatory compliance as the company grows.

This strategic enhancement is backed by significant investor confidence. The Columbus-based biotech, which spun out of Nationwide Children's Hospital, secured approximately $33 million in a Series A financing round led by the Ohio Innovation Fund, with participation from key investors like Rev1 Ventures, JobsOhio Growth Capital, and the Cystic Fibrosis Foundation. This funding provides the financial runway needed to support the expanded operational and developmental efforts now being led by Doran and Hall.

The Minds Behind the Mission

The newly appointed executives bring a wealth of complementary experience perfectly suited to Clarametyx's current growth trajectory. Their combined expertise forms a powerful synergy of scientific innovation and clinical execution.

Dr. Veronica Hall, a core member of the leadership team since the company's inception in 2020, has been a driving force behind the CMTX-101 program. Her work was instrumental in advancing the therapy from a foundational concept to a clinical-stage asset. Before Clarametyx, Dr. Hall served as Senior Director at Emergent BioSolutions, where she managed a substantial R&D portfolio, secured over $75 million in yearly R&D revenue, and led efforts that resulted in a $1.6 billion strategic alliance award. Her two decades of experience in life sciences, from her Ph.D. at Rice University to a postdoctoral fellowship at the National Cancer Institute, provide the deep scientific acumen needed to navigate the complexities of drug development.

Dr. Brendan Doran joined Clarametyx in 2025 and quickly made a significant impact, driving the rapid completion of the CMTX-101 Phase 2a study in cystic fibrosis. His background is a unique blend of clinical practice and operational leadership. Prior to Clarametyx, he was Head of Clinical Operations at CinRx Pharma and held leadership roles at the large contract research organization CTI Clinical Trial and Consulting Services. A licensed pharmacist who has practiced in hospital settings, Dr. Doran possesses a ground-level understanding of patient care and trial execution. This experience is critical for optimizing clinical development pathways and ensuring patient engagement, a key factor in successful trial outcomes.

Targeting the Root of Chronic Infection

Clarametyx is tackling one of the most formidable challenges in modern medicine: bacterial biofilms. These slimy, protective matrices encase colonies of bacteria, rendering them highly resistant to both antibiotics and the body's own immune system. They are a primary driver of persistent inflammation and infection in a host of chronic respiratory diseases.

The company’s technology is designed to be both “pathogen-agnostic” and “immune-enabling.” Instead of targeting a specific type of bacteria, CMTX-101 targets a universal structural component of the biofilm itself. By rapidly disrupting this shield, the therapy exposes the vulnerable bacteria within, allowing the immune system and conventional antibiotics to effectively clear the infection.

Recent topline data from the Phase 1b/2a study of CMTX-101 in adults with cystic fibrosis (CF) demonstrated the promise of this approach. The study met its primary endpoint for safety and tolerability. More significantly, it showed compelling signs of efficacy. Participants treated with CMTX-101 saw a 77% reduction in neutrophil elastase, a key biomarker of the inflammation that causes progressive lung damage. At the same time, their lung function, measured by FEV1, remained stable, and a majority of subjects showed a greater than 70% reduction in the bacterial load of Pseudomonas aeruginosa, a common and dangerous pathogen in CF.

Addressing a Persistent Unmet Need

Despite revolutionary advances like CFTR modulators, chronic lung infection and the resulting inflammatory damage remain the leading cause of mortality for patients with cystic fibrosis. The daily treatment burden is high, and the threat of antibiotic-resistant infections is constant. Clarametyx’s approach directly addresses this persistent unmet need by offering a new way to break the cycle of infection and inflammation.

Building on the successful CF study, the company is now planning a Phase 2 trial for CMTX-101 in patients with bronchiectasis, another chronic respiratory condition characterized by biofilm-driven infections and inflammation. The platform's potential extends further, with possible applications in chronic obstructive pulmonary disease (COPD) and nontuberculous mycobacterial (NTM) lung disease.

With its technology validated by promising early data and its leadership team fortified for the challenges ahead, Clarametyx is strategically positioned to advance a new class of therapies. The company's focused efforts aim to transform the treatment paradigm for millions of patients worldwide who continue to battle the devastating consequences of chronic bacterial diseases.